2015: "To examine the emergence potential (the potential to infect humans) of circulating bat CoVs, we built a chimeric virus encoding a novel, zoonotic CoV spike protein -from the RsSHC014-CoV sequence that was isolated from Chinese horseshoe bats" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797993/#__ffn_sectitle
Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts USA
"Using the SARS-CoV reverse genetics system2, we generated and characterized a chimeric virus expressing the spike of bat coronavirus SHC014 in a mouse-adapted SARS-CoV backbone."
"The results indicate that group 2b viruses encoding the SHC014 spike..replicate efficiently in primary human airway cells and achieve in vitro titers equivalent to epidemic strains of SARS-CoV."
THEY DID NOT CONSIDER T-CELLS!
"Evaluation of available SARS-based immune-therapeutic and prophylactic modalities revealed poor efficacy; both monoclonal antibody and vaccine approaches failed to neutralize and protect from infection with CoVs using the novel spike protein."
"Evaluation of available SARS-based immune-therapeutic and prophylactic modalities revealed poor efficacy; both monoclonal antibody and vaccine approaches failed to neutralize and protect from infection with CoVs using the novel spike protein."
"Wild-type SARS-CoV (Urbani), mouse-adapted SARS-CoV (MA15) and chimeric SARS-like CoVs were cultured on Vero E6 cells (obtained from United States Army Medical Research Institute of Infectious Diseases)"
"experiments were similar to those using an HIV-based pseudovirus, prepared as previously described10, and examined on HeLa cells (Wuhan Institute of Virology)
"Human lungs for HAE cultures were procured under University of North Carolina at Chapel Hill Institutional Review Board–approved protocols. "
These studies were initiated before the US Government Deliberative Process Research Funding Pause on Selected Gain-of-Function Research Involving Influenza, MERS and SARS Viruses ( http://www.phe.gov/s3/dualuse/Documents/gain-of-function.pdf)
"This paper has been reviewed by the funding agency, the NIH. Continuation of these studies was requested, and this has been approved by the NIH.
SARS-CoV is a select agent."
SARS-CoV is a select agent."
These are the authors of the research, should we not have heard a lot more from them since the SARSCov2 outbreak?
Departments of Epidemiology, Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina USA
National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas USA
National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas USA
Wuhan Lab was well on this path in 2010. Thread: https://twitter.com/robinmonotti/status/1306440729552711681?s=19
Will we get an answer? https://twitter.com/robinmonotti/status/1309379114458021889?s=19
Ralph Baric: "We can engineer a virus without leaving any trace. We engineered it so antibodies would not work": THEY DID NOT CONSIDER T-CELLS https://twitter.com/Carlo_bis/status/1308607670920843265/video/1